Abstract
Mutations in FLT3 receptor tyrosine kinase are common targets in Acute Myeloid Leukemia (AML); however, FLT3 targeted therapy shows limited success due to development of resistance. Ceramide, a bioactive sphingolipid,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have